MT 2654
Alternative Names: MT-2654Latest Information Update: 17 Feb 2023
At a glance
- Originator Medicago
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Influenza virus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 17 Feb 2023 Discontinued - Phase-I for Influenza virus infections (In the elderly, Prevention) (Parenteral) (Mitsubishi Tanabe Pharma Corporation pipeline, February 2023)
- 08 Feb 2021 Phase-I clinical trials in Influenza virus infections (Prevention, In the elderly) (Parenteral) before February 2021 (Mitsubishi Tanabe Pharma pipeline, February 2021)
- 08 Feb 2021 Preclinical trials in Influenza virus infections (Prevention) in Canada (Parenteral) before February 2021 (Mitsubishi Tanabe Pharma pipeline, February 2021)